Pharma BD Deal Intelligence
A rare PE win in pharma generics — STADA roughly doubled EBITDA and is being sold on to CapVest at a premium — but the Russia "exit" was cosmetic and got seized by Putin anyway in 2025.
Full analysis, sources & comparables →Fierce Pharma noted Bain and Cinven were forced to raise their bid twice under pressure from Elliott Management and Active Ownership, suggesting the buyers…
STADA reported FY2017 generics segment sales up 6% to €1,361.7M and group sales of ~€2.3B; management guided continued mid-single-digit growth under new PE…
Looking back, Bain and Cinven 'transformed STADA from a traditional German generics business into a leading, diversified global healthcare platform with…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Bain Capital and Cinven (Nidda Healthcare Holding AG) successfully completed a renewed voluntary public takeover of STADA at EUR 66.25/share (EUR 65.53 + EUR 0.72 dividend), valuing the German generics/biosimilars/branded OTC company at approximately EUR 5.3B (~$6.1B). 63.85% of shares tendered. The PE owners later transformed STADA into a global generics/specialty platform.
A rare PE win in pharma generics — STADA roughly doubled EBITDA and is being sold on to CapVest at a premium — but the Russia "exit" was cosmetic and got seized by Putin anyway in 2025.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bain Capital Private Equity / Cinven Partners (Nidda Healthcare Holding AG) / STADA Arzneimittel (this deal) | 2017 | $6.1B | 82 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
| Pamplona Capital Management, LLP / PAREXEL International Corporation | 2017 | $5.0B | 90 |
← Browse all deals · How we score deals
More: 2017 deals · Other deals